Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced on February 18, 2026 that its FDA‑cleared INSPIRA™ ART100 system has been deployed at a New York academic medical center ranked among the state’s top 10 hospitals. The deployment marks the company’s first structured commercial evaluation in a Tier‑1 U.S. hospital and provides a real‑world setting to refine clinical protocols and assess broader institutional adoption.
The move expands Inspira’s presence in the most competitive U.S. hospital market and signals that the ART100 is meeting the operational and clinical demands of top‑tier providers. The deployment is a key milestone in the company’s strategy to convert high‑profile evaluations into a sustainable commercial pipeline, potentially accelerating revenue generation in a market that has historically been slow to adopt new respiratory support technologies.
Inspira’s financial profile remains challenging. For the first half of 2025 the company reported revenue of $289,000 and a net loss of $6.4 million, with cash on hand of $5.779 million as of December 31, 2024. The company has also entered an at‑the‑market equity program to raise up to $2.02 million in ordinary shares. The deployment at the New York center therefore represents a critical opportunity to generate incremental revenue and demonstrate the ART100’s value proposition in a high‑visibility environment.
Mike Hershkovitz, Global VP Sales, said, “This deployment represents a continued execution of our U.S. commercial strategy. Following our recent interaction with other leading healthcare providers, entering another leading institution in New York State demonstrates that the ART100 meets the operational and clinical demands of top‑tier U.S. healthcare providers. Our focus remains on converting these high‑profile evaluations into a sustainable commercial pipeline and further expanding our footprint across key U.S. markets.”
Beyond the ART100, Inspira is developing the INSPIRA™ ART500 oxygenation platform and the HYLA™ continuous, non‑invasive blood sensor platform. The company’s recent vendor approval from Clalit Health Services and its planned showcase of the ART100 at the American Society of Extracorporeal Technology conference in March 2026 underscore a broader strategy to broaden its product portfolio and market reach.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.